Last reviewed · How we verify
Lidoderm 5 % Topical Patch
Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission when applied topically to the skin.
Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission when applied topically to the skin. Used for Postherpetic neuralgia (localized neuropathic pain), Localized pain relief.
At a glance
| Generic name | Lidoderm 5 % Topical Patch |
|---|---|
| Also known as | lidocaine patch, Lidoderm |
| Sponsor | Oregon Health and Science University |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that penetrates the skin and reversibly inhibits sodium influx in nerve membranes, preventing depolarization and conduction of pain impulses. The 5% patch formulation delivers lidocaine transdermally to provide localized analgesia without systemic absorption. This mechanism allows sustained pain relief in the area of application for up to 12 hours.
Approved indications
- Postherpetic neuralgia (localized neuropathic pain)
- Localized pain relief
Common side effects
- Skin irritation or erythema at application site
- Dermatitis or allergic contact dermatitis
- Localized edema
Key clinical trials
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting (PHASE1, PHASE2)
- Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects (PHASE1)
- Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects (PHASE1)
- Topical Lidocaine Patch in Low Back Pain (PHASE4)
- Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata (NA)
- Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients (PHASE2)
- Fractional CO2 Laser Fenestration and Steroid Delivery in HS Lesions (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidoderm 5 % Topical Patch CI brief — competitive landscape report
- Lidoderm 5 % Topical Patch updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI